Clinical Trial Update: Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers [Phase 1]

View source ↗

Summary

Reports Phase 1 dose-optimization results for the VXA-G1.1-NN candidate in healthy volunteers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Norovirus Gastroenteritis

Drugs mentioned

• VXA-G1.1-NN (adenoviral-vector Norovirus vaccine)

Snippet

Sponsor: Vaxart | Conditions: Norovirus Gastroenteritis | Phase 1 | Status: COMPLETED